NuVasive Inc (NUVA)

NuVasive invests in advanced materials science portfolio with first-of-its-kind porous PEEK technology

Latest clearance unites RELINE­® Small Stature fixation portfolio with the MAGEC@ System and introduces a new design with 5.0 millimeter rod to be unveiled at Scoliosis Research Society 52nd Annual Meeting

The Company's plans include expansion of state-of-the-art surgeon education lab, creation of a new technology innovation center and extension of work space as talent base grows

Mr. Cattarina Brings 40+ Years of Leadership Experience in Healthcare IT and Medical Devices

Financial and operational veteran to support Company's continued growth strategy and profitability goals

And a management shakeup helps push down NuVasive.

New structure designed to align strategy and innovation, integrate global commercial channels and transform business operations

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AIG, ALSK, GNE, GUID, HTH, LPI, NUVA, PIRS, QRVO, S, TTMI Downgrades: ARRS, BPMC, CONE, CRAY, EFII, GIL, GKOS, HYH, SUM Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

The most recent short interest data was recently released for the 04/13/2017 settlement date, and Nuvasive Inc is one of the most shorted stocks of the Russell 3000, based on 10.25 "days to cover" versus the median component at 5.14. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

In trading on Monday, shares of Nuvasive Inc touched a new 52-week high of $77.88/share. That's a 56.17% rise, or $28.01 per share from the 52-week low of $49.87 set back on 04/22/2016.

FDA 510(k) Clearance for CoRoent® Small Interbody™ System Includes Indication for Treatment of Cervical Disc Degeneration at up to Four Contiguous Levels

NICE Guidance Supported by Literature Review of More than 200 Peer-Reviewed Articles Primarily Reflecting Experience with NuVasive's Industry-Leading XLIF Procedure

This patient-monitoring device-maker has plenty of room for growth.

The most recent short interest data was recently released for the 01/13/2017 settlement date, and Nuvasive Inc is one of the most shorted stocks of the Russell 3000, based on 6.67 "days to cover" versus the median component at 5.04. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Recognition of the market's inertia seems to be growing.